Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study
Clinical evidence on prophylactic antibiotics for transarterial chemoembolization (TACE) to prevent liver abscess is limited because liver abscess is a rare event. This study aimed to analyse the association between prophylactic antibiotic use for TACE and the occurrence of liver abscess after TACE....
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2021-10, Vol.27 (10), p.1514.e5-1514.e10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1514.e10 |
|---|---|
| container_issue | 10 |
| container_start_page | 1514.e5 |
| container_title | Clinical microbiology and infection |
| container_volume | 27 |
| creator | Yoshihara, Shingo Yamana, Hayato Akahane, Manabu Kishimoto, Miwa Nishioka, Yuichi Noda, Tatsuya Matsui, Hiroki Fushimi, Kiyohide Yasunaga, Hideo Kasahara, Kei Imamura, Tomoaki |
| description | Clinical evidence on prophylactic antibiotics for transarterial chemoembolization (TACE) to prevent liver abscess is limited because liver abscess is a rare event. This study aimed to analyse the association between prophylactic antibiotic use for TACE and the occurrence of liver abscess after TACE.
Using the nationwide Diagnosis Procedure Combination database in Japan, we retrospectively identified patients who underwent TACE for hepatic cancer between July 2010 and March 2017. The primary outcome was liver abscess requiring procedural intervention within 30 days of TACE. Secondary outcomes included 30-day in-hospital mortality and length of stay. Propensity score matching was performed to adjust for potential confounding factors and compare outcomes between patients with and without prophylactic antibiotics.
Among 167 544 eligible patients, 134 712 received antibiotics and 32 832 did not. In the matched cohort of 29 211 pairs, the proportion of patients with liver abscess requiring procedural intervention was significantly lower in the antibiotics group than in the no-antibiotics group (0.08% vs. 0.22%, p 0.001; relative risk (95% confidence interval), 0.35 (0.22–0.57); absolute risk reduction, 0.0014 (0.0008–0.0021); and number needed to treat, 696 (476–1223)). There was no significant difference in 30-day in-hospital mortality between the groups. The length of stay was longer in the antibiotics group than in the no-antibiotics group (median, 10 vs. 9 days, p |
| doi_str_mv | 10.1016/j.cmi.2021.01.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479423476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X21000410</els_id><sourcerecordid>2479423476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-d346eef0d006e93328ed5d5eed9dd1402c6c6d2ecc1d8e45c6bb5ad51fd200843</originalsourceid><addsrcrecordid>eNp9UU2LFDEQDaK46-oP8CI5eumxkk4y03paFr9gwYuCt5CuVDMZujtjkh4Z_4X_2DSzehSKVB1evdR7j7GXAjYChHlz2OAUNhKk2MBa6hG7Fsp0DZhOPK6z6HbNVrXfr9iznA8AINtWPWVX9TVag7xmv29zjhhcCXHmPZWfRDM_pnjcn0eHJSB3cwl9iOu4ZOJDTLwkN2eXCqXgRo57miJNfRzDrwuPmz2PiEtKNCPxOPAxnChx12eknN9yxxOVFPOR6hcn4hj3MRWey-LPz9mTwY2ZXjz0G_btw_uvd5-a-y8fP9_d3jeoW10aXyUQDeABDHVtK3fktddEvvNeKJBo0HhJiMLvSGk0fa-d12LwEmCn2hv2-sJb1f5YKBc7hXreOLqZ4pKtVNtOyVZtTYWKCxTrzTnRYI8pTC6drQC7JmEPtiZh1yQsrLXSv3qgX_qJ_L-Nv9ZXwLsLgKrIU6BkM4bVLx9StcX6GP5D_wfEE558</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479423476</pqid></control><display><type>article</type><title>Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yoshihara, Shingo ; Yamana, Hayato ; Akahane, Manabu ; Kishimoto, Miwa ; Nishioka, Yuichi ; Noda, Tatsuya ; Matsui, Hiroki ; Fushimi, Kiyohide ; Yasunaga, Hideo ; Kasahara, Kei ; Imamura, Tomoaki</creator><creatorcontrib>Yoshihara, Shingo ; Yamana, Hayato ; Akahane, Manabu ; Kishimoto, Miwa ; Nishioka, Yuichi ; Noda, Tatsuya ; Matsui, Hiroki ; Fushimi, Kiyohide ; Yasunaga, Hideo ; Kasahara, Kei ; Imamura, Tomoaki</creatorcontrib><description>Clinical evidence on prophylactic antibiotics for transarterial chemoembolization (TACE) to prevent liver abscess is limited because liver abscess is a rare event. This study aimed to analyse the association between prophylactic antibiotic use for TACE and the occurrence of liver abscess after TACE.
Using the nationwide Diagnosis Procedure Combination database in Japan, we retrospectively identified patients who underwent TACE for hepatic cancer between July 2010 and March 2017. The primary outcome was liver abscess requiring procedural intervention within 30 days of TACE. Secondary outcomes included 30-day in-hospital mortality and length of stay. Propensity score matching was performed to adjust for potential confounding factors and compare outcomes between patients with and without prophylactic antibiotics.
Among 167 544 eligible patients, 134 712 received antibiotics and 32 832 did not. In the matched cohort of 29 211 pairs, the proportion of patients with liver abscess requiring procedural intervention was significantly lower in the antibiotics group than in the no-antibiotics group (0.08% vs. 0.22%, p 0.001; relative risk (95% confidence interval), 0.35 (0.22–0.57); absolute risk reduction, 0.0014 (0.0008–0.0021); and number needed to treat, 696 (476–1223)). There was no significant difference in 30-day in-hospital mortality between the groups. The length of stay was longer in the antibiotics group than in the no-antibiotics group (median, 10 vs. 9 days, p < 0.001).
Prophylactic antibiotic use in patients undergoing TACE was associated with a reduced occurrence of liver abscess requiring procedural intervention.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2021.01.014</identifier><identifier>PMID: 33465502</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotic Prophylaxis ; Chemoembolization, Therapeutic ; Hospital Mortality ; Humans ; Length of Stay ; Liver abscess ; Liver Abscess - drug therapy ; Liver Abscess - epidemiology ; Liver Neoplasms - drug therapy ; Propensity Score ; Prophylactic antibiotics ; Real-world data ; Retrospective Studies ; Transarterial chemoembolization ; Treatment Outcome</subject><ispartof>Clinical microbiology and infection, 2021-10, Vol.27 (10), p.1514.e5-1514.e10</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-d346eef0d006e93328ed5d5eed9dd1402c6c6d2ecc1d8e45c6bb5ad51fd200843</citedby><cites>FETCH-LOGICAL-c535t-d346eef0d006e93328ed5d5eed9dd1402c6c6d2ecc1d8e45c6bb5ad51fd200843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33465502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshihara, Shingo</creatorcontrib><creatorcontrib>Yamana, Hayato</creatorcontrib><creatorcontrib>Akahane, Manabu</creatorcontrib><creatorcontrib>Kishimoto, Miwa</creatorcontrib><creatorcontrib>Nishioka, Yuichi</creatorcontrib><creatorcontrib>Noda, Tatsuya</creatorcontrib><creatorcontrib>Matsui, Hiroki</creatorcontrib><creatorcontrib>Fushimi, Kiyohide</creatorcontrib><creatorcontrib>Yasunaga, Hideo</creatorcontrib><creatorcontrib>Kasahara, Kei</creatorcontrib><creatorcontrib>Imamura, Tomoaki</creatorcontrib><title>Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Clinical evidence on prophylactic antibiotics for transarterial chemoembolization (TACE) to prevent liver abscess is limited because liver abscess is a rare event. This study aimed to analyse the association between prophylactic antibiotic use for TACE and the occurrence of liver abscess after TACE.
Using the nationwide Diagnosis Procedure Combination database in Japan, we retrospectively identified patients who underwent TACE for hepatic cancer between July 2010 and March 2017. The primary outcome was liver abscess requiring procedural intervention within 30 days of TACE. Secondary outcomes included 30-day in-hospital mortality and length of stay. Propensity score matching was performed to adjust for potential confounding factors and compare outcomes between patients with and without prophylactic antibiotics.
Among 167 544 eligible patients, 134 712 received antibiotics and 32 832 did not. In the matched cohort of 29 211 pairs, the proportion of patients with liver abscess requiring procedural intervention was significantly lower in the antibiotics group than in the no-antibiotics group (0.08% vs. 0.22%, p 0.001; relative risk (95% confidence interval), 0.35 (0.22–0.57); absolute risk reduction, 0.0014 (0.0008–0.0021); and number needed to treat, 696 (476–1223)). There was no significant difference in 30-day in-hospital mortality between the groups. The length of stay was longer in the antibiotics group than in the no-antibiotics group (median, 10 vs. 9 days, p < 0.001).
Prophylactic antibiotic use in patients undergoing TACE was associated with a reduced occurrence of liver abscess requiring procedural intervention.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic Prophylaxis</subject><subject>Chemoembolization, Therapeutic</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Liver abscess</subject><subject>Liver Abscess - drug therapy</subject><subject>Liver Abscess - epidemiology</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Propensity Score</subject><subject>Prophylactic antibiotics</subject><subject>Real-world data</subject><subject>Retrospective Studies</subject><subject>Transarterial chemoembolization</subject><subject>Treatment Outcome</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2LFDEQDaK46-oP8CI5eumxkk4y03paFr9gwYuCt5CuVDMZujtjkh4Z_4X_2DSzehSKVB1evdR7j7GXAjYChHlz2OAUNhKk2MBa6hG7Fsp0DZhOPK6z6HbNVrXfr9iznA8AINtWPWVX9TVag7xmv29zjhhcCXHmPZWfRDM_pnjcn0eHJSB3cwl9iOu4ZOJDTLwkN2eXCqXgRo57miJNfRzDrwuPmz2PiEtKNCPxOPAxnChx12eknN9yxxOVFPOR6hcn4hj3MRWey-LPz9mTwY2ZXjz0G_btw_uvd5-a-y8fP9_d3jeoW10aXyUQDeABDHVtK3fktddEvvNeKJBo0HhJiMLvSGk0fa-d12LwEmCn2hv2-sJb1f5YKBc7hXreOLqZ4pKtVNtOyVZtTYWKCxTrzTnRYI8pTC6drQC7JmEPtiZh1yQsrLXSv3qgX_qJ_L-Nv9ZXwLsLgKrIU6BkM4bVLx9StcX6GP5D_wfEE558</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Yoshihara, Shingo</creator><creator>Yamana, Hayato</creator><creator>Akahane, Manabu</creator><creator>Kishimoto, Miwa</creator><creator>Nishioka, Yuichi</creator><creator>Noda, Tatsuya</creator><creator>Matsui, Hiroki</creator><creator>Fushimi, Kiyohide</creator><creator>Yasunaga, Hideo</creator><creator>Kasahara, Kei</creator><creator>Imamura, Tomoaki</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study</title><author>Yoshihara, Shingo ; Yamana, Hayato ; Akahane, Manabu ; Kishimoto, Miwa ; Nishioka, Yuichi ; Noda, Tatsuya ; Matsui, Hiroki ; Fushimi, Kiyohide ; Yasunaga, Hideo ; Kasahara, Kei ; Imamura, Tomoaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-d346eef0d006e93328ed5d5eed9dd1402c6c6d2ecc1d8e45c6bb5ad51fd200843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic Prophylaxis</topic><topic>Chemoembolization, Therapeutic</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Liver abscess</topic><topic>Liver Abscess - drug therapy</topic><topic>Liver Abscess - epidemiology</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Propensity Score</topic><topic>Prophylactic antibiotics</topic><topic>Real-world data</topic><topic>Retrospective Studies</topic><topic>Transarterial chemoembolization</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshihara, Shingo</creatorcontrib><creatorcontrib>Yamana, Hayato</creatorcontrib><creatorcontrib>Akahane, Manabu</creatorcontrib><creatorcontrib>Kishimoto, Miwa</creatorcontrib><creatorcontrib>Nishioka, Yuichi</creatorcontrib><creatorcontrib>Noda, Tatsuya</creatorcontrib><creatorcontrib>Matsui, Hiroki</creatorcontrib><creatorcontrib>Fushimi, Kiyohide</creatorcontrib><creatorcontrib>Yasunaga, Hideo</creatorcontrib><creatorcontrib>Kasahara, Kei</creatorcontrib><creatorcontrib>Imamura, Tomoaki</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshihara, Shingo</au><au>Yamana, Hayato</au><au>Akahane, Manabu</au><au>Kishimoto, Miwa</au><au>Nishioka, Yuichi</au><au>Noda, Tatsuya</au><au>Matsui, Hiroki</au><au>Fushimi, Kiyohide</au><au>Yasunaga, Hideo</au><au>Kasahara, Kei</au><au>Imamura, Tomoaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>27</volume><issue>10</issue><spage>1514.e5</spage><epage>1514.e10</epage><pages>1514.e5-1514.e10</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Clinical evidence on prophylactic antibiotics for transarterial chemoembolization (TACE) to prevent liver abscess is limited because liver abscess is a rare event. This study aimed to analyse the association between prophylactic antibiotic use for TACE and the occurrence of liver abscess after TACE.
Using the nationwide Diagnosis Procedure Combination database in Japan, we retrospectively identified patients who underwent TACE for hepatic cancer between July 2010 and March 2017. The primary outcome was liver abscess requiring procedural intervention within 30 days of TACE. Secondary outcomes included 30-day in-hospital mortality and length of stay. Propensity score matching was performed to adjust for potential confounding factors and compare outcomes between patients with and without prophylactic antibiotics.
Among 167 544 eligible patients, 134 712 received antibiotics and 32 832 did not. In the matched cohort of 29 211 pairs, the proportion of patients with liver abscess requiring procedural intervention was significantly lower in the antibiotics group than in the no-antibiotics group (0.08% vs. 0.22%, p 0.001; relative risk (95% confidence interval), 0.35 (0.22–0.57); absolute risk reduction, 0.0014 (0.0008–0.0021); and number needed to treat, 696 (476–1223)). There was no significant difference in 30-day in-hospital mortality between the groups. The length of stay was longer in the antibiotics group than in the no-antibiotics group (median, 10 vs. 9 days, p < 0.001).
Prophylactic antibiotic use in patients undergoing TACE was associated with a reduced occurrence of liver abscess requiring procedural intervention.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33465502</pmid><doi>10.1016/j.cmi.2021.01.014</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2021-10, Vol.27 (10), p.1514.e5-1514.e10 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2479423476 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Anti-Bacterial Agents - therapeutic use Antibiotic Prophylaxis Chemoembolization, Therapeutic Hospital Mortality Humans Length of Stay Liver abscess Liver Abscess - drug therapy Liver Abscess - epidemiology Liver Neoplasms - drug therapy Propensity Score Prophylactic antibiotics Real-world data Retrospective Studies Transarterial chemoembolization Treatment Outcome |
| title | Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T12%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20prophylactic%20antibiotic%20use%20for%20transarterial%20chemoembolization%20and%20occurrence%20of%20liver%20abscess:%20a%20retrospective%20cohort%20study&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Yoshihara,%20Shingo&rft.date=2021-10-01&rft.volume=27&rft.issue=10&rft.spage=1514.e5&rft.epage=1514.e10&rft.pages=1514.e5-1514.e10&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2021.01.014&rft_dat=%3Cproquest_cross%3E2479423476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479423476&rft_id=info:pmid/33465502&rft_els_id=S1198743X21000410&rfr_iscdi=true |